Clinical Characteristics of 211 Elderly Patients With Previously Untreated AML
| . | Median . | Range . |
|---|---|---|
| . | . | . |
| Age . | 68 . | 58-88 . |
| . | . | . |
| . | No. . | Percent . |
| Sex | ||
| Female | 89 | 42 |
| Male | 122 | 58 |
| Disease onset | ||
| Secondary | 50 | 24 |
| De novo | 161 | 76 |
| FAB type | ||
| M1 | 58 | 27 |
| M2 | 70 | 33 |
| M4 | 21 | 10 |
| M5 | 19 | 9 |
| M6 | 8 | 4 |
| M7 | 1 | 0.5 |
| M0 | 24 | 11 |
| M0/M7 | 1 | 0.5 |
| Myeloid NOS | 9 | 4 |
| Treatment arm | ||
| Ara-C + DNR + rhG-CSF | 106 | 50 |
| Ara-C + DNR + Placebo | 105 | 50 |
| . | Median . | Range . |
|---|---|---|
| . | . | . |
| Age . | 68 . | 58-88 . |
| . | . | . |
| . | No. . | Percent . |
| Sex | ||
| Female | 89 | 42 |
| Male | 122 | 58 |
| Disease onset | ||
| Secondary | 50 | 24 |
| De novo | 161 | 76 |
| FAB type | ||
| M1 | 58 | 27 |
| M2 | 70 | 33 |
| M4 | 21 | 10 |
| M5 | 19 | 9 |
| M6 | 8 | 4 |
| M7 | 1 | 0.5 |
| M0 | 24 | 11 |
| M0/M7 | 1 | 0.5 |
| Myeloid NOS | 9 | 4 |
| Treatment arm | ||
| Ara-C + DNR + rhG-CSF | 106 | 50 |
| Ara-C + DNR + Placebo | 105 | 50 |
AML FAB-M3/M3v patients were excluded from entry onto this SWOG trial (9031).